1-(3-Chlorophenyl)piperazine
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Image:MCPP 2D.png | |
| Image:MCPP3d.png | |
| 1-(3-Chlorophenyl)piperazine
| |
| Systematic (IUPAC) name | |
| 1-(3-Chlorophenyl)piperazine | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C10H13ClN2 |
| Mol. mass | 196.676 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | hepatic |
| Half life | ? |
| Excretion | renal |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | oral |
1-(3-Chlorophenyl)piperazine (or meta-chlorophenylpiperazine, mCPP) is a piperazine-based 5-HT receptor agonist that has been used as a challenge drug in MDMA research. In the mid-2000s, it has shown up in legal alternatives to illegal stimulants in New Zealand, and pills sold as ecstasy in Europe and the United States.
mCPP is known to induce headaches in humans,[1][1] and has been used for testing potential anti-migraine medications.[1] Up to 10% of people who take mCPP will develop a migraine headache, and 90% of individuals who commonly suffer from migraines will have an attack induced by mCPP. This has tended to limit the use of mCPP as a recreational drug.
Legal status
In the US: unscheduled
In New Zealand: unscheduled
In Denmark: Banned [1]
In Germany: Banned
See also
- Benzylpiperazine (BZP)
- Trifluoromethylphenylpiperazine (TFMPP)
- Etoperidone
- Trazodone -- metabolises to mCPP in vivo
References
External links
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
